Skip to content
DataLookout
Menu

NCT04785989

In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved at least 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 24 versions: 21 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 23 words
    • Primary and study completion pushed from Oct 2026 to Apr 2027
  2. Minor Site contact updatedv23
  3. Notable Primary and study completion dates: Oct 2025 to Oct 2026v22
  4. Notable Primary and study completion dates: Oct 2024 to Oct 2025v20
  5. Notable Phase: Not applicable to Not specifiedv19
Show 15 earlier versionsHide 15 earlier versions
  1. Notable Phase: Early Phase 1 to Not applicablev18
  2. Minor Start date changed from estimate of Jun 2022 to Jun 13, 2022v16
  3. Minor Start date: May 2022 to Jun 2022v15
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v14
  5. Minor Start date: Apr 2022 to May 2022v13
  6. Minor Start date: Mar 2022 to Apr 2022v11
  7. Minor Start date: Jan 2022 to Mar 2022v10
  8. Minor Start date: Dec 2021 to Jan 2022v9
  9. Minor Start date: Nov 2021 to Dec 2021v8
  10. Minor Start date: Oct 2021 to Nov 2021v7
  11. Notable Start date: Aug 2021 to Oct 2021v6
  12. Notable Start date: Jun 2021 to Aug 2021v5
  13. Minor Start date: May 2021 to Jun 2021v4
  14. Minor Start date: Apr 2021 to May 2021v3
  15. Minor Start date: Mar 2021 to Apr 2021v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Amount of [U-13C]glucose incorporation into metabolites in normal and leukemic lymphocytes: Liquid chromatography-mass spectrometry (LCMS) pharmacokinetic analysis
Timeframe: up to 2 hours (± 5 minutes)
Amount of [U-13C15N]L-glutamine incorporation into metabolites in normal and leukemic lymphocytes: LCMS pharmacokinetic analysis
Timeframe: up to 2 hours (± 5 minutes)

Arms and interventions

Group A: Healthy volunteers

Healthy volunteers are defined as people without a history of cancer

Group B subset-1: Treatment naïve CLL(Chronic Lymphocytic Leukemia) patients with low disease burden

Participants with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0.

Group B subset-2: Treatment naïve CLL patients with low disease burden

Participants with low disease burden CLL (Chronic Lymphocytic Leukemia) defined as confined to Rai stage 0.

Group C:Treatment naïve CLL patients with high systemic disease burden

Treatment naïve CLL patients with high systemic disease burden

Other: [U-13C]glucose, [13C5]glutamine

Sites

1 site in 1 country

  • University of WisconsinMadison, Wisconsin, United States